29Q

(5R)-5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol

29Q as a free ligand exists in 2 entries. Examples include: 4MME 4MMF

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name(5R)-5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
Identifiers(5R)-5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
FormulaC16 H13 Cl N2 O
Molecular Weight284.74
TypeNON-POLYMER
Isomeric SMILESO[C@]1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1
InChIInChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2/t16-/m1/s1
InChIKeyZPXSCAKFGYXMGA-MRXNPFEDSA-N

Chemical Details

Formal Charge0
Atom Count33
Chiral Atom Count1
Chiral AtomsC
Bond Count36
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00579 Different stereochemistry
NameMazindol
Groupsapproved
DescriptionMazindol is a tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Synonyms
  • Mazindol
  • Mazindolo
  • Mazindolum
  • Sanorex
SaltsMazindol hydrochloride
Brand Names
  • Sanorex
  • Dimagrir
  • Fagolip Plus
  • Mazanor
  • Teronac
Affected OrganismHumans and other mammals
IndicationUsed in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
PharmacologyMazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.
Mechanism of actionAlthough the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.
Route of administrationOral
Categories
  • Adrenergic Agents
  • Adrenergic Uptake Inhibitors
  • Alimentary Tract and Metabolism
  • Antiobesity Preparations, Excl. Diet Products
  • Central Nervous System Agents
ATC-CodeA08AA05
CAS number22232-71-9
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682